Amgen’s Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II
ORR 28% Versus 37% In Trial Prior To Accelerated Approval
Lumakras data at ESMO in KRAS G12C-mutated lung cancer bested docetaxel on PFS, and largely on safety. OS was better for chemotherapy, but the trial was not powered for statistical significance on OS.
